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Identity 
Other names: clathrin heavy chain; KIAAOO34; 
CLH-17 
HGNC (Hugo): CLTC 
Location: 17q23 
Note 




32 exons, 6111 bp mRNA. 
Protein 
Description 
Clathrin is the major protein constituent of the coat that 
surrounds organelles (cytoplasmic vesicles) to mediat  
selective protein transport. Clathrin coats are involved 
in receptor-mediated endocytosis and intracellular 
trafficking and recycling of receptors, which accounts 
for its characteristic punctate cytoplasmic and 
perinuclear cellular distribution. Structurally, clathrin is 
a triskelion (three-legged) shaped protein complex that
is composed of a trimer of heavy chains (CLTC) each 
bound to a single light chain. CLTC is a 1675 amino 
acid residue protein encoded by a gene consisting of 32 
exons. Its known domains include a N-terminal  
globular domain (residues 1-494) that interacts with 
adaptor proteins (AP-1, AP-2, b-arrestin), a light c ain-
binding region (residues 1074-1552), and a 





Mediate endocytosis of transmembrane receptors. 
Implicated in 
Anaplasic large cell lymphoma (ALCL) 
with t(2;17)(p23;q23) --> ALK - CLTC 
Disease 
ALCL are high grade non Hodgkin lymphomas; ALK+ 
ALCL are ALCL where ALK is involved in a fusion 
gene; ALK+ ALCL represent 50 to 60 % of ALCL 
cases (they are CD30+, ALK+); belong to the 
"cytoplasmic ALK+" subset. 
Prognosis 
Although presenting as a high grade tumour, a 80% 
five yr survival is associated with this anomaly. 
Hybrid/Mutated gene 
5' CLTC - 3' ALK 
Abnormal protein 
NH2 CLTC - COOH ALK 
Inflammatory myofibroblastic tumors 
with t(2;17)(p23;q23) 
Note 
In these tumors, the fusion point in CLTC is identical, 
being at amino acid 1634 (corresponding to the 3' end 
of exon 31 of CLTC), such that almost all of CLTC is 
included in the fusion protein, including its 
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trimerization domain. As a fusion partner, CLTC has 
been postulated to provide CLTC-ALK with 
deregulated expression driven by its constitutively 
activated promoter and constitutive oligomerization of 
the chimeric protein via the CLTC multimerization 
domains normally used for clathrin coat assembly. 
Since ALK is a tyrosine kinase that is activated by 
cross-phosphorylation following ligand binding, 
CLTC-ALK-induced oligomerization may result in a 
constitutively activated ALK tyrosine kinase domain. 
In this sense, CLTC is likely to function in CLTC-ALK 
as other prototypical «dimerizing translocation 
partners" in fusions involving tyrosine kinase genes. 
Disease 





5' CLTC - 3' ALK. 
Xp11 renal translocation carcinoma with 
t(X;17)(p11;q23) 
Note 
In the CLTC-TFE3 fusion, the fusion point on CLTC is 
at amino acid 932 (corresponding to the end of exon 
17), thereby excluding the CLTC trimerization domain 
from the predicted fusion protein. As in other TFE3 
gene fusions, the nuclear localization and DNA binding 
domains of TFE3 are retained in CLTC-TFE3. Based 
on these features and existing data on other TFE3 
fusion proteins, CLTC-TFE3 may act as an aberrant 
transcription factor, with the CLTC promoter driving 
constitutive expression. 
Disease 
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